Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin 
Quarterly Data

Microsoft Excel

Two-Component Disaggregation of ROE

Bristol-Myers Squibb Co., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Mar 31, 2026 36.25% = 8.41% × 4.31
Dec 31, 2025 38.19% = 7.83% × 4.87
Sep 30, 2025 32.55% = 6.23% × 5.22
Jun 30, 2025 28.96% = 5.33% × 5.43
Mar 31, 2025 31.16% = 5.86% × 5.32
Dec 31, 2024 -54.78% = -9.66% × 5.67
Sep 30, 2024 -42.34% = -7.75% × 5.46
Jun 30, 2024 -38.44% = -6.91% × 5.56
Mar 31, 2024 -37.28% = -6.21% × 6.01
Dec 31, 2023 27.27% = 8.43% × 3.23
Sep 30, 2023 28.57% = 9.08% × 3.15
Jun 30, 2023 24.91% = 8.52% × 2.92
Mar 31, 2023 22.97% = 7.75% × 2.96
Dec 31, 2022 20.37% = 6.53% × 3.12
Sep 30, 2022 20.44% = 6.80% × 3.01
Jun 30, 2022 20.30% = 6.59% × 3.08
Mar 31, 2022 19.79% = 6.07% × 3.26

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance over the analyzed period is characterized by a period of steady growth, a severe contraction during 2024, and a subsequent recovery through early 2026. The relationship between operational profitability and capital structure shows a high degree of sensitivity, where fluctuations in asset returns were significantly amplified by changes in financial leverage.

Return on Assets (ROA)
A consistent upward trajectory is observed from March 2022 through September 2023, with ROA rising from 6.07% to a peak of 9.08%. This trend reversed sharply in March 2024, where ROA fell into negative territory, reaching a low of -9.66% by December 2024. A recovery phase began in March 2025, with returns trending upward to reach 8.41% by March 2026.
Financial Leverage
Leverage remained relatively stable between 2.92 and 3.26 from March 2022 to December 2023. A significant structural shift occurred in March 2024, where the leverage ratio spiked to 6.01. While the ratio trended downward following this peak, it remained elevated compared to historical levels, settling at 4.31 by March 2026.
Return on Equity (ROE)
The ROE reflects the compounded effect of the ROA and leverage trends. From March 2022 to September 2023, ROE grew from 19.79% to 28.57%. In 2024, the combination of negative asset returns and increased financial leverage resulted in a severe erosion of equity returns, with ROE plummeting to -54.78% by year-end. The recovery in 2025 and 2026 was rapid; the higher leverage environment, coupled with returning positive ROA, propelled ROE to new highs, peaking at 38.19% in December 2025 before moderating to 36.25% in March 2026.

The analysis indicates that the 2024 period was a point of extreme volatility. The simultaneous occurrence of negative ROA and a sharp increase in financial leverage created a multiplicative effect that accelerated equity losses. However, the retention of higher leverage levels into 2025 and 2026 acted as a catalyst for ROE expansion once operational profitability returned to positive levels.

AI Ask an analyst for more


Three-Component Disaggregation of ROE

Bristol-Myers Squibb Co., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Mar 31, 2026 36.25% = 15.01% × 0.56 × 4.31
Dec 31, 2025 38.19% = 14.64% × 0.54 × 4.87
Sep 30, 2025 32.55% = 12.57% × 0.50 × 5.22
Jun 30, 2025 28.96% = 10.58% × 0.50 × 5.43
Mar 31, 2025 31.16% = 11.38% × 0.52 × 5.32
Dec 31, 2024 -54.78% = -18.53% × 0.52 × 5.67
Sep 30, 2024 -42.34% = -15.30% × 0.51 × 5.46
Jun 30, 2024 -38.44% = -14.06% × 0.49 × 5.56
Mar 31, 2024 -37.28% = -13.50% × 0.46 × 6.01
Dec 31, 2023 27.27% = 17.83% × 0.47 × 3.23
Sep 30, 2023 28.57% = 18.44% × 0.49 × 3.15
Jun 30, 2023 24.91% = 17.62% × 0.48 × 2.92
Mar 31, 2023 22.97% = 15.95% × 0.49 × 2.96
Dec 31, 2022 20.37% = 13.71% × 0.48 × 3.12
Sep 30, 2022 20.44% = 14.29% × 0.48 × 3.01
Jun 30, 2022 20.30% = 14.04% × 0.47 × 3.08
Mar 31, 2022 19.79% = 13.31% × 0.46 × 3.26

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The return on equity (ROE) analysis reveals a period of extreme volatility centered around the 2024 fiscal year, characterized by a severe contraction followed by a robust recovery. While asset efficiency showed a consistent upward trend, the overall return was primarily dictated by drastic swings in net profit margins and a significant shift in the financial leverage profile.

Net Profit Margin
Profitability demonstrated steady growth through 2023, peaking at 18.44% in September. This trend reversed sharply in 2024, with the margin collapsing into negative territory and reaching a trough of -18.53% by December 31, 2024. A recovery trend emerged in 2025, with margins returning to positive levels and stabilizing at 15.01% by March 2026.
Asset Turnover
Operational efficiency remained the most stable component of the DuPont disaggregation. A gradual and consistent increase is observed, with the ratio improving from 0.46 in March 2022 to 0.56 by March 2026. This indicates a sustained improvement in the ability to generate revenue from the asset base, independent of the volatility experienced in net income.
Financial Leverage
A substantial increase in financial leverage occurred at the start of 2024, where the ratio jumped from a historical average of approximately 3.0 to a peak of 6.01. Although the ratio began a gradual decline throughout 2025 and early 2026, ending at 4.31, it remained significantly higher than the 2022-2023 levels. This heightened leverage acted as a multiplier, exacerbating the negative ROE during the 2024 margin collapse and accelerating the ROE recovery once profitability returned.
Return on Equity (ROE)
The interaction of the three components resulted in an ROE that grew from 19.79% in early 2022 to a high of 28.57% in September 2023. The subsequent crash in profit margins, combined with increased leverage, drove ROE to a low of -54.78% by December 2024. The recovery phase saw ROE peak at 38.19% in December 2025, settling at 36.25% by March 2026, a level higher than the pre-2024 period due to the sustained increase in financial leverage.

AI Ask an analyst for more


Two-Component Disaggregation of ROA

Bristol-Myers Squibb Co., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Mar 31, 2026 8.41% = 15.01% × 0.56
Dec 31, 2025 7.83% = 14.64% × 0.54
Sep 30, 2025 6.23% = 12.57% × 0.50
Jun 30, 2025 5.33% = 10.58% × 0.50
Mar 31, 2025 5.86% = 11.38% × 0.52
Dec 31, 2024 -9.66% = -18.53% × 0.52
Sep 30, 2024 -7.75% = -15.30% × 0.51
Jun 30, 2024 -6.91% = -14.06% × 0.49
Mar 31, 2024 -6.21% = -13.50% × 0.46
Dec 31, 2023 8.43% = 17.83% × 0.47
Sep 30, 2023 9.08% = 18.44% × 0.49
Jun 30, 2023 8.52% = 17.62% × 0.48
Mar 31, 2023 7.75% = 15.95% × 0.49
Dec 31, 2022 6.53% = 13.71% × 0.48
Sep 30, 2022 6.80% = 14.29% × 0.48
Jun 30, 2022 6.59% = 14.04% × 0.47
Mar 31, 2022 6.07% = 13.31% × 0.46

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Assets (ROA) exhibits significant volatility over the analyzed period, characterized by an initial growth phase, a sharp contraction into negative territory, and a subsequent recovery.

Net Profit Margin
The net profit margin served as the primary driver of ROA fluctuations. An upward trend was observed from March 2022 through September 2023, with margins peaking at 18.44%. This was followed by a severe decline throughout 2024, where margins fell to a low of -18.53% by December 31, 2024. A recovery phase commenced in March 2025, with margins returning to positive territory and trending upward to 15.01% by March 31, 2026.
Asset Turnover
Asset turnover remained relatively stable with a consistent, gradual improvement throughout the period. Starting at 0.46 in March 2022, the ratio climbed steadily to 0.56 by March 31, 2026. Notably, asset efficiency continued to improve even during the period of negative profitability in 2024, indicating that the contraction in ROA was not caused by a decline in asset utilization but rather by the collapse in net profit margins.
ROA Disaggregation Analysis
The relationship between the two components reveals that ROA is highly sensitive to profitability swings. The peak ROA of 9.08% in September 2023 coincided with the highest recorded profit margin. Conversely, the trough of -9.66% in December 2024 was driven exclusively by the margin decline, as asset turnover actually increased during that interval. The recovery to an ROA of 8.41% by March 2026 is the result of restored profit margins acting upon a more efficient asset base.

AI Ask an analyst for more